Eton Pharmaceuticals CBO Sells $3.23M in Stock After Option Exercise
ETON has more than doubled off its 52-week low of $13.085.
Summary
Eton Pharmaceuticals' Chief Business Officer, David Krempa, sold $3.23 million worth of common stock after exercising options, significantly reducing his direct holdings.
Key Events · Ownership and Investor Activity · ETON
-
Chief Business Officer Sells Shares
David Krempa, Chief Business Officer, sold 100,000 shares of common stock for a total value of $3,229,923.25. The sales occurred between May 22 and May 27, 2026, at prices ranging from $31.47 to $35.00 per share.
-
Option Exercise Precedes Sale
Prior to the sales, Mr. Krempa exercised options to acquire 87,794 shares of common stock for a total cost of $204,052.52, with exercise prices ranging from $1.37 to $3.58 per share.
-
Reduced Direct Holdings
Following these transactions, Mr. Krempa's direct ownership in Eton Pharmaceuticals decreased to 125,609 shares.
-
Timing Follows Positive News
This significant insider sale occurs after a period of strong company performance, including FDA approvals, product acquisitions, and robust Q1 2026 financial results, which led to a recent surge in the stock price.
Analysis · ETON · Life Sciences
Chief Business Officer David Krempa sold a significant portion of his holdings, totaling $3.23 million, after exercising options. This transaction, occurring after a period of strong financial results and a recent stock surge, represents an insider monetizing vested equity and reducing their direct ownership in the company.
At the time of this filing, ETON was trading at $33.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $887.5M. The 52-week trading range was $13.09 to $35.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.